Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PersoMed-I for post-pubertal newly diagnosed medulloblastoma
NL-OMON53731Phase 2Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2023
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sonidegib in medulloblastoma (4 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival by central review in SHH subgroup. Planned start Feb 2023; status: withdrawn.
02
Drugs
sonidegib
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NL-OMON53731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53731.